Hypertension pharmacogenomics: Current status and future directions

Current Opinion in Molecular Therapeutics

Volumn 7, Issue 3, 2005, Pages 218-225

  Johnson, Julie A ^a   Turner, Stephen T ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b Mayo Clinic   (United States)

Author keywords

blockers; Angiotensin receptor blockers; Angiotensin converting enzyme inhibitors; Antihypertensive drugs; Calcium channel blockers; Diuretics; Hypertension; Pharmacogenetics; Pharmacogenomics; Polymorphisms

Indexed keywords

ADDUCIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; FUROSEMIDE; HYDROCHLOROTHIAZIDE; IMIDAPRIL; IRBESARTAN; LISINOPRIL; METOPROLOL; PERINDOPRIL; PLACEBO;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; CHRONIC DISEASE; CLINICAL TRIAL; DRUG CLASSIFICATION; DRUG FATALITY; ESSENTIAL HYPERTENSION; GENE REPLICATION; GENETIC ANALYSIS; GENETIC VARIABILITY; HEART INFARCTION; HUMAN; NORTH AMERICA; PATIENT CARE; PHARMACOGENETICS; PHARMACOGENOMICS; PHENOTYPE; REVIEW; SAMPLE SIZE; SINGLE NUCLEOTIDE POLYMORPHISM; STROKE;

HUMANS; HYPERTENSION; PHARMACOGENETICS;

EID: 20344396337     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Heart Disease and Stroke Statistics - 2004 Update. American Heart Association, Dallas, Texas, USA (2003).
2. Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, Sorlie P: The burden of adult hypertension in the United States 1999 to 2000: A rising tide. Hypertension (2004) 44(4):398-404.
3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ et al: The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. J Am Med Assoc (2003) 289(19):2560-2571.
4. Veterans Administration Cooperative Study Group on Antihypertensive Agents: Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. II. Results of long-term therapy. J Am Med Assoc (1982) 248(16):2004-2011.
5. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R, Gottdiener J, Ramirez EA et al: Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med (1993) 328(13):914-921.
6. Preston RA, Materson BJ, Reda DJ, Williams DW, Hamburger RJ, Cushman WC, Anderson RJ: Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. J Am Med Assoc (1998) 280(13):1168-1172.
7. Materson BJ: Variability in response to antihypertensive drug treatment. Hypertension (2004) 43(6):1166-1167.
8. Dickerson JE, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ: Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet (1999) 353(9169):2008-2013.
9. Deary AJ, Schumann AL, Murfet H, Haydock SF, Foo RS, Brown MJ: Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs. J Hypertens (2002) 20(4):771-777.
10. Morgan TO, Anderson AI, MacInnis RJ: ACE inhibitors, β-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am J Hypertens (2001) 14(3):241-247.
11. Psaty BM, Smith NL, Heckbert SR, Vos HL, Lemaitre RN, Reiner AP, Siscovick DS, Bis J, Lumley T, Longstreth WT Jr, Rosendaal FR: Diuretic therapy, the α-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. J Am Med Assoc(2002) 287(13):1680-1689.
12. Turner ST, Chapman AB, Schwartz GL, Boerwinkle E: Effects of endothelial nitric oxide synthase, α-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide. Am J Hypertens (2003) 16(10):834-839
13. Sciarrone MT, Stella P, Barlassina C, Manunta P, Lanzani C, Bianchi G, Cusi D: ACE and α-adducin polymorphism as markers of individual response to diuretic therapy. Hypertension (2003) 41(3):398-403.
14. Schwartz GL, Turner ST, Chapman AB, Boerwinkle E: Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide. Kidney Int (2002) 62(5):1718-1723.
15. Turner ST, Schwartz GL, Chapman AB, Boerwinkle E: C825T polymorphism of the G protein β3-subunit and antihypertensive response to a thiazide diuretic. Hypertension (2001) 37(2 Pt 2):739-743.
16. Terra SG, Pauly DF, Lee CR, Patterson JH, Adams KF, Schofield RS, Belgado BS, Hamilton KK, Aranda JM, Hill JA, Yarandi HN et al: β-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. Clin Pharmacol Ther (2005) 77(3):127-137.
17. 1-Adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med (2003) 9(10):1300-1305.
18. 1-Adrenergic receptor polymorphisms and left ventricular remodeling changes in response to β-blocker therapy. Pharmacogenetics Genomics (2005) 15: in press.
19. Zineh I, Beitelshees AL, Gaedigk A, Walker JR, Pauly DF, Eberst K, Leeder JS, Phillips MS, Gelfand CA, Johnson JA: Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther (2004) 76(6):536-544.
20. Kohno M, Yokokawa K, Minami M, Kano H, Yasunari K, Hanehira T, Yoshikawa J: Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors. Am J Med (1999) 106(5):544-549.
21. Sasaki M, Oki T, Iuchi A, Tabata T, Yamada H, Manabe K, Fukuda K, 3Abe M, Ito S: Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiographic studies. J Hypertens (1996) 14(12):1403-1408.
22. Prasad A, Narayanan S, Husain S, Padder F, Waclawiw M, Epstein N, Quyyumi AA: Insertion-deletion polymorphism of the ACE gene modulates reversibility of endothelial dysfunction with ACE inhibition. Circulation (2000) 102(1):35-41.
23. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest (1990) 86(4):1343-1346.
24. Mizuiri S, Hemmi H, Inoue A, Takano M, Kadomatsu S, Tanimoto H, Tanegashima M, Hayashi I, Fushimi T, Hasegawa A: Renal hemodynamic changes induced by captopril and angiotensin-converting enzyme gene polymorphism. Nephron (1997) 75(3):310-314.
25. Clement DL, De Buyzere ML, De Bacquer DA, de Leeuw PW, Duprez DA, Fagard RH, Gheeraert PJ, Missault LH, Braun JJ, Six RO, Van Der Niepen P et al: Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med (2003) 348(24):2407-2415.
26. Ohkubo T, Imai Y, Tsuji I, Nagai K, Kato J, Kikuchi N, Nishiyama A, Aihara A, Sekino M, Kikuya M, Ito S et al: Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: A population-based observation in Ohasama, Japan. J Hypertens (1998) 16(7):971-975.
27. Verdecchia P: Prognostic value of ambulatory blood pressure: Current evidence and clinical implications. Hypertension (2000) 35(3):844-851.
28. Kikuya M, Ohkubo T, Asayama K, Metoki H, Obara T, Saito S, Hashimoto J, Totsune K, Hoshi H, Satoh H, Imai Y: Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality: The Ohasama study. Hypertension (2005) 45(2):240-245.
29. Bochud M, Bovet P, Elston RC, Paccaud F, Falconnet C, Maillard M, Shamlaye C, Bumier M: High heritability of ambulatory blood pressure in families of East African descent. Hypertension (2005) 45(3):445-450.
30. Ragot S, Genes N, Vaur L, Herpin D: Comparison of three blood pressure measurement methods for the evaluation of two antihypertensive drugs: Feasibility, agreement, and reproducibility of blood pressure response. Am J Hypertens (2000) 13(6 Pt 1):632-639.
31. Stergiou GS, Baibas NM, Gantzarou AP, Skeva II, Kalkana CB, Roussias LG, Mountokalakis TD: Reproducibility of home, ambulatory, and clinic blood pressure: Implications for the design of trials for the assessment of antihypertensive drug efficacy. Am J Hypertens (2002) 15(2 Pt 1):101-104.
32. Fotherby MD, Potter JF: Reproducibility of ambulatory and clinic blood pressure measurements in elderly hypertensive subjects. J Hypertens (1993) 11(5):573-579.
33. Conway J: Ambulatory blood pressure and clinical trials. J Hypertens Suppl (1991) 9(3):S57-S60.
34. Moller DS, Dideriksen A, Sorensen S, Madsen LD, Pedersen EB: Accuracy of telemedical home blood pressure measurement in the diagnosis of hypertension. J Hum Hypertens (2003) 17(8):549-554.
35. Stergiou GS, Efstathiou SP, Skeva II, Baibas NM, Kalkana CB, Mountokalakis TD: Assessment of drug effects on blood pressure and pulse pressure using clinic, home and ambulatory measurements. J Hum Hypertens (2002) 16(10):729-735.
36. Parati G, Omboni S, Mancia G: Difference between office and ambulatory blood pressure and response to antihypertensive treatment. J Hypertens (1996) 14(6):791-797.
37. Mancia G, Omboni S, Parati G, Ravogli A, Villani A, Zanchetti A: Lack of placebo effect on ambulatory blood pressure. Am J Hypertens (1995) 8(3):311-315.
38. Mutti E, Trazzi S, Omboni S, Parati G, Mancia G: Effect of placebo on 24-h non-invasive ambulatory blood pressure. J Hypertens (1991) 9(4):361-364.
39. Imai Y, Ohkubo T, Hozawa A, Tsuji I, Matsubara M, Araki T, Chonan K, Kikuya M, Satoh H, Hisamichi S, Nagai K: Usefulness of home blood pressure measurements in assessing the effect of treatment in a single-blind placebo-controlled open trial. J Hypertens (2001) 19(2):179-185.
40. International HapMap Project. World Wide Web Site (2005) (http://www.hapmap.org)
41. 1-Adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther (2003) 74(1):44-52.
42. Johnson JA, Lima JJ: Drug receptor/effector polymorphisms and pharmacogenetics: Current status and challenges. Pharmacogenetics (2003) 13(9):525-534.
43. Cusi D, Barlassina C, Azzani T, Casari G, Citterio L, Devoto M, Glorioso N, Lanzani C, Manunta P, Righetti M, Rivera R et al: Polymorphisms of α-adducin and salt sensitivity in patients with essential hypertension. Lancet (1997) 349(9062):1353-1357.
44. Glorioso N, Manunta P, Filigheddu F, Troffa C, Stella P, Barlassina C, Lombardi C, Soro A, Dettori F, Parpaglia PP, Alibrandi MT et al: The role of α-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study. Hypertension (1999) 34(4 Pt 1):649-654.
45. Frazier L, Turner ST, Schwartz GL, Chapman AB, Boerwinkle E: Multilocus effects of the renin-angiotensin-aldosterone system genes on blood pressure response to a thiazide diuretic. Pharmacogenomics J (2004) 4(1):17-23.
46. 1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin Pharmacol Ther(2003) 74(4):372-379.
47. 389Gly) affects blood pressure response to β-blockade. Clin Pharmacol Ther (2003) 73(4):366-371.
48. 1-adrenoceptor does not influence blood pressure or heart rate response to β-blockade in hypertensive subjects. Clin Sci (2000) 99(3):233-238.
49. 1-adrenergic receptor blockade in patients with essential hypertension. Clin Cardiol (2004) 27(6):347-350.
50. 2-Adrenoceptor gene polymorphisms and blood pressure variations in East Anglian Caucasians. J Hypertens (2000) 18(6):687-693.
51. sα gene with essential hypertension and response to β-blockade. Hypertension (1999) 34(1):8-14.
52. Kurland L, Liljedahl U, Karlsson J, Kahan T, Malmqvist K, Melhus H, Syvanen AC, Lind L: Angiotensinogen gene polymorphisms: Relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. Am J Hypertens (2004) 17(1):8-13.
53. Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman KP, Nystrom F, Hagg A, Lind L: Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J Hypertens (2001) 19(10):1783-1787.
54. Dudley C, Keavney B, Casadei B, Conway J, Bird R, Ratcliffe P: Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: Investigation of renin-angiotensin system genes. J Hypertens (1996) 14(2):259-262.
55. Li X, Du Y, Huang X: Correlation of angiotensin-converting enzyme gene polymorphism with effect of antihypertensive therapy by angiotensin-converting enzyme inhibitor. J Cardiovasc Pharmacol Ther (2003) 8(1):25-30.
56. Ohmichi N, Iwai N, Uchida Y, Shichiri G, Nakamura Y, Kinoshita M: Relationship between the response to the angiotensin converting enzyme inhibitor imidapril and the angiotensin converting enzyme genotype. Am J Hypertens (1997) 10(8):951-955.
57. Stavroulakis GA, Makris TK, Krespi PG, Hatzizacharias AN, Gialeraki AE, Anastasiadis G, Triposkiadis P, Kyriakidis M: Predicting response to chronic antihypertensive treatment with fosinopril: The role of angiotensin-converting enzyme gene polymorphism. Cardiovasc Drugs Ther (2000) 14(4):427-432.
58. Yu H, Zhang Y, Liu G: Relationship between polymorphism of the angiotensin-converting enzyme gene and the response to angiotensin-converting enzyme inhibition in hypertensive patients. Hypertens Res (2003) 26(11):881-886.
59. Harrap SB, Tzourio C, Cambien F, Poirier O, Raoux S, Chalmers J, Chapman N, Colman S, Leguennec S, MacMahon S, Neal B et al: The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition. Hypertension (2003) 42(3):297-303.
60. Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman P, Nystrom F, Hagg A, Lind L: Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: Result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. Am J Hypertens (2002) 15(5):389-393.
61. Ortlepp JR, Hanrath P, Mevissen V, Kiel G, Borggrefe M, Hoffmann R: Variants of the CYP1192 gene predict response to therapy with candesartan. Eur J Pharmacol (2002) 445(1-2):151-152.
62. Benetos A, Cambien F, Gautier S, Ricard S, Safar M, Laurent S, Lacolley P, Poirier O, Topouchian J, Asmar R: Influence of the angiotensin II type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals. Hypertension (1996) 28(6):1081-1084.
63. Hingorani A, Jia H, Stevens PA, Hopper R, Dickerson JE, Brown MJ: Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens (1995) 13(12 Pt 2):1602-1609.
64. Kaplan NM, Lieberman E, Neal W: Kaplan's Clinical Hypertension. 6th Edition, Lippincott, Williams and Wilkins, Baltimore, MD, USA (1994).